Latest news with #SynopsisBioconBiologicsLtd

Time of India

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Synopsis Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats osteoporosis and bone loss. This approval follows a similar authorization from the European Commission. It allows commercialization across the EU and EEA.